About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Our Science Discuva Platform Scientific Literature & Publications Investors Investor Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial October 3, 2018 By Mary Alvarado
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial October 3, 2018 By Mary Alvarado
